LKB1 mutations have been observed in approximately 20% of human cervical cancer patients [10] and activation of mTORC1, a downstream target of LKB1 signaling, has been observed in 54% of human cervical adenocarcinoma patients [63]. This evidence concerns the gene STK11 and cervical cancer.